Outcomes After Stereotactic Body Radiation for Hepatocellular Carcinoma in Patients With Child-Pugh A Versus Child-Pugh B/C Cirrhosis.

Autor:	Diamond BH; Department of Radiation Oncology, Tufts Medical Center, Boston, Massachusetts., Banson K; Department of Radiation Oncology, New York University, New York, New York., Ayash J; Department of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts., Lee P; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Shukla UC; New Mexico Cancer Center, Albuquerque, New Mexico., Jones G; Department of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts., Rava P; Department of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts., Fitzgerald TJ; Department of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts., Sioshansi S; Department of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Jazyk:	angličtina
Zdroj:	Advances in radiation oncology [Adv Radiat Oncol] 2024 Nov 04; Vol. 9 (12), pp. 101631. Date of Electronic Publication: 2024 Nov 04 (Print Publication: 2024).
DOI:	10.1016/j.adro.2024.101631
Abstrakt:	Purpose: For patients with hepatocellular carcinoma (HCC), stereotactic body radiation therapy (SBRT) has emerged as a locoregional treatment. Our purpose was to report outcomes in patients with HCC with Child-Pugh A (CP A) versus Child-Pugh B or C (CP B/C) liver dysfunction treated with SBRT. Methods and Materials: A retrospective analysis of 80 patients with HCC, with a total of 94 tumors treated with SBRT, was conducted at a single institution. Outcomes were compared between patients with CP A (n = 51) and CP B/C (n = 29) liver dysfunction. Outcomes of interest included local control, overall survival (OS), and toxicity. Results: Median tumor size was 3.2 cm. There were 59 tumors included in the CP A cohort and 35 tumors in the CP B/C cohort. Median radiation dose was 50 Gy in 5 fractions for the CP A cohort and 40 Gy in 5 fractions for the CP B/C cohort. The rates of pathologic complete response were similar between the 2 groups at 63% for the CP A group and 61% for the CP B/C group. The estimated 1-year local control rates were similar between the 2 groups at 93% for the CP A group and 91% for the CP B/C group ( P = .59). The 1-year OS for the CP A group was 85%, whereas the 1-year OS for the CP B/C group was 61% ( P = .19). There was a 5.9% rate of grade 3+ toxicity in the CP A group and a 20.7% rate of grade 3+ toxicity in the CPB/C group. Conclusions: Our findings suggest that SBRT is feasible and effective in patients with both CP A and CP B/C liver dysfunction with similar rates of local control and pathologic complete response despite lower radiation doses in the CP B/C cohort. In patients with more advanced CP B/C cirrhosis, toxicities were higher and must be weighed against possible treatment benefits. Further studies characterizing the optimal role of SBRT in patients with advanced cirrhosis are warranted. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu